Follow your Heart.
Analyze your heart, anywhere, anytime. Introducing the Coala Heart Monitor, a unique medical system that records your heart sounds and ECG in just a minute.
Smart, cloud-based algorithms analyze instantly and detect for Atrial Fibrillation (based on P-wave detection and RR variability), 9 other arrhythmia's and the ability to help detect murmurs.
Results presented in the Coala App and Coala Care Cloud Portal within seconds. Connect your doctor to the Coala Care Portal for smart remote assessments.
No more sticky electrodes, patches or wires. No limits in time. You're in control, engaged and it's simply smart medical technology for your heart.
Coala Life's first, multi-award winning solutions were launched in 2017 to enable daily monitoring and analysis of the heart. The Coala is now available in both consumer and professional configurations to help predict and aid the early detection of heart diseases, and with direct connection to caregivers, based on the user's permission. Ground-breaking digital services open for everyone, based on more than 10 years of Swedish R&D.
Coala Life is backed by industry leaders and approximately 12 million USD in funding. The mission is to develop the first medical solutions based on AI to predict and detect early signs of heart disease, alleviate worries and reduce the burden on healthcare. The future is here now.
Record your ECG and heart sound simultaneously.
You analyze your heart by simply holding the Coala for 30 seconds towards your chest, followed by 30 seconds of thumb-ECG. The patent pending double ECG recording maximizes quality, precision and accuracy - with less artifacts and need to redo the recording.
Results presented within seconds in the Coala App.
The analysis is performed securely and with highest performing processing speeds in the cloud (Microsoft Azure) based on smart, validated algorithms. The Coala analyzes for 10 different cardiac pathologies, including AF, PVC, PAC, AV block II etc. The results of the analysis is presented within seconds to the user in the Coala App.
Coalas state-of-the-art algorithms analyzes based on P-wave detection and RR variability, unlike conventional AF screening solutions that typically only detect for RR variability. For more info on the analyzing categories and specifications, see here.
It's not just a mobile AF detector, it's a complete cloud based cardiac service.
The results are accessed and available instantly in the Coala Care Portal. A smart platform where users grant clinicians right to access and assess their data. The Coala Care Portal enables further remote analysis, auscultation, ability to create PDF's, download the raw data and communicate with users. The Coala Care Portal can be easily accessed from any online computer or tablet. Integrate it with your EMR.
No sticky, degrading patches and no separate electrodes. It's all integrated and intelligent.
The Coala's unique, multi-patented technology is based on more than 10 years of R&D. The Coala consists of a unique high performance sensor that records and digitizes the sounds of your heart, and with three smart electrodes that record and analyze your heart impulses by ECG. The digital platform with 1000 Hz, 24 bit ECG-technology delivers excellent high quality ECG.
World-class clinical accuracy with P-wave and R-R based analysis.
The analytic, smart algorithms used in the Coala system are based on extensive research and long experience with analysis of arrhythmias and ECG signals. The algorithms are based on research presented in 40+ scientific journal papers, and have been used in hundreds of thousands of ECGs. All developed in collaboration with researchers at the Karolinska Hospital and Lund Universities in Sweden.
For more info on the analyzing categories and specifications, see here.
Minimized risk of artifacts and secure Bluetooth transmission.
The Coala does not require a special phone case or access to your smartphone's microphone. You can keep your headphones and hearing aids on and with Bluetooth connectivity your data is securely transmitted with less risk of electrical and mechanical interferences. Coala App is available for both iOS and Android.
Smart murmur detection.
The Coala Care portal has a unique digital Phonocardiogram (PCG) with smart algorithms to correlate the heart sound recording with ECG. The tool provides the caregiver with interpretation support to help detect signs of murmurs and other noise disturbances in the heart.
Predict and prevent with AI.
Coala's smart algorithms, coupled with Artificial Intelligence and neural networks offers the ability to predict and ultimately prevent heart disease. A medical revolution, and simply nothing like it.
Introducing the Coala Pro for Rx and patient engaged cardiac assessments.
The Coala Pro (blue in color) is developed and offered to professional users to enable efficient multi-patient, high performance arrhythmia assessments as well as diagnosing and managing patients with AFIB in daily life. Ideal to track ECG recordings and interpretations between patient visits. Clinical yield and sensitivity at its best - simply digital telemedicine 2.0.
Coala Pro X: Smart cardiac assessments as-a-service
Introducing the Coala Pro X, a new service for patient centered, digital cardiac investigations in a home environment. Upon order, a Coala Heart Monitor Pro is sent directly to the patient for montoring, which simplifies handling, eliminates waiting times, and more efficient remtote cardicac assessmenrt through any connected computer. Download the product note here.
Used by leading Swedish healthcare providers.
The Coala Pro is used at leading University Hospitals, cardiology clinics and by primary care physicians to enable smart, patient engaged cardiac assessments. Designed to enable more cost-effective assessments, improved profitability and reduced need of specialist referrals. Interested too? Contact us here.
When user engagement is important.
The Coala Heart Monitor is used by thousands of Swedish consumers in their everyday life to help detect early signs of heart disease, alleviate worries and offload healthcare. Hundreds of clinicians and healthcare providers are connected to the Coala Care platform. User satisfaction is >90%.
Follow your trends in the app, and include other variables such as blood pressure.
The Coala App enables you to trend your data, and include other clinical variables as blood pressure and weight. The Coala iOS app is also compatible with the Apple Health app to integrate heart beat data.
A complete eco-system with the ability to connect any caregiver.
Any caregiver can be connected to the Coala Care platform. It offers the ability to connect your personal MD, your cardiologist, perhaps your occupational health physician, or just any caregiver you want to remotely follow your heart. For more info, contact us here.
A smart digital service available for everyone, anywhere*
The consumer version is offered with different service plans. The Premium plan offers unlimited recordings and analysis, long term secure storage of data in the cloud, and direct connection to HeartCareLine™ (Hjärtupplysningen™) a health care provider (currently only available in Sweden).* The Coala is currently only offered in Sweden, but can easily be adapted for other regions and licensed as a system.
Simply the solution for your everyday life.
Developed to enable preventive and early detection of heart disease by smart, validated algorithms for instant analysis of the heart. Helps to alleviate worries and powered by an eco-system that can be connected to any caregiver. The Coala is designed to help improve healthcare productivity and profitability - for more info, contact us here.
Enabling groundbreaking clinical studies.
The Coala is ideal for smart, digital studies. The RedHeart Study is one example - the world's largest clinical study to date on the female heart using digital health tools to assess palpitations and quality of life, run by Karolinska Institutet. For more info, click here.
Coala Life has been awarded with over 15 industry recognitions and honors for its innovations. If you also want to be part of the success story, partner or offer your patients the Coala as well - simply contact us here.
"We believe in a world where mankind is digitized, connected and screened for early detection and disease prevention."
Coala Life is a Swedish digital health venture disrupting the field of cardiac diagnostics. The company has launched a multi-prize winning portfolio of cardiac monitoring solutions based on the Coala Heart Monitor, a cloud-based product and service for real-time analysis of the heart. Solutions are sold direct to individuals as well as to healthcare professionals to enable more efficient and digital cardiac assessments. It’s about digitizing the heart by the power and engagement of the individual, and using smart algorithms to help predict and prevent heart disease.
Sales up and running in Sweden, broad IP in place, CE-approved Class IIa medical device and 510(k) in process. Core team are ex. St Jude Medical and the company has an Apple Manufacturing License and tight collaborations with industry leaders as Bayer and Microsoft. Approximately 12 million USD raised to date and an impressive portfolio of international awards support the company.
We make it possible for everyone to monitor their heart.
THE CORE TEAM
Philip Siberg Co-founder and CEO, Johanna Tulkki COO, Magnus Samuelsson CTO, Lovisa Fasth E-Commerce & Digital Manager, Titti Lundgren CMO, Hsinti Rydberg, QAM (not in photo), Malin Sendén, CXM (not in photo), Anna Hernegran Business Development Manager (not in photo) and Ulf Tossman Co-founder and Medical Director (not in photo).
Philip has founded, built, globally expanded and sold a number of medical device companies, both venture funded and publicly traded. Johanna, Hsinti and Magnus bring in successful careers from the cardiac diagnostics company Radi Medical that was acquired by St. Jude Medical, the global leader in solutions for the heart. Titti is the marketing super woman with a career as CEO and CMO in a number of medical and consumer oriented companies. Lovisa joined us as the digital expert with studies and work in New York. Malin joined us from Global Kinetics and leading a roll-out of patient-centered, digital, Parkinson solutions. Anna joins us following a successful career within Philips Healthcare driving cardiology and imaging solutions to market. Ulf is Co-founder with a PhD in Medical Science and many years of experience as Medical Director, investor and business developer in the Life science field.
Liselott Kilaas (chair), Johanna Öberg, Ebba Fåhraeus, Sören Olofsson, Anders Nyrén, Anders Rodebjer and Jan Flood.
Liselott has an impressive career as, among others, CEO of Aleris, the largest private healthcare provider in the Nordics. Liselott has been on the Board of Telenor ASA and the Central Bank of Norway, to mention a few assignments. Sören has been the CEO of some of Swedens largest hospital's, he laid the foundation of e-health in Sweden and he advises the European Union on digitization of health. Johanna is the CEO of Memira, the largest healthcare provder in the Nordics within eye lens replacement surgery. Anders N has an honorary PhD in economics and is one of Sweden's most prominent industrialists, he just left as Board Member of Ericsson. Ebba is a super star of entrepreneurship and innovation, and among others, the CEO of SmiLe Incubator. Anders R has medical degree and is the super corporate finance guy. Jan is a great lawyer and one of the founding investors of the company.
clinical advisory board
Tord Juhlin, MD, PhD, Senior consultant and Cardiologist, Skåne University Hospital. Tord is also the Chairman of the Swedish Cardiology Societies Heart Rhythm Group (HRG). Hans-Jörgen Nilsson, MD, PhD, Workstream Lead Cardiology, Senior consultant and Cardiologist, Skåne University Hospital. Hans-Jörgen is currently active in the cardiology implementation of new region wide EMR system in Region Skåne. Claes Held, MD, PhD, Senior consultant and associate Professor in Cardiology, Akademiska sjukhuset Uppsala (The Uppsala University Hospital). Claes is also a researcher active at Uppsala Clinical Research Center (UCR)
The Coala investors include some of Swedens most prominent doctors, professors, entrepreneurs, life science experts, business angels, institutional investors, family offices, the management team and lots of ordinary people sharing our mission and vision. Thank you.
Lots of fantastic cardiologists, GP's, nurses, professors, researchers, ambassadors within healthcare, experts on algorithms and signal processing, industrial designers, hw- and sw-developers, our manufacturing partners, everyone within Bayer, LloydsPharmacy, Medhelp, Microsoft, 1,6 miljonerklubben, other sales partners, super marketeers, lots of other experts in a number of fields, and most important of all - our customers. Thanks to you all - it's a team effort needed to help win the battle against the world's leading cause of death.
Milestones and News 2018-1821
Performance assessment study presented at American Heart Association 2018, and published in Circulation, read more here.
Coala Life elected by research firm PUBLIC as one of the leaders of the digital transformation of public healthcare, see link here.
New clinical performance data of Coala presented at the annual fall meeting of the Swedish Clinical Physiologists, see link here.
Launch of Coala Pro X - digital, cardiac assessments as-a-service, see link.
Coala presents at the Health 2.0 conference in Santa Clara, US, see link.
Coala attends and presents at the Digital Health Pavilion of ESC 2018, the largest cardiovascular meeting in the world.
Agreement signed with Capio, one of Europe’s largest healthcare companies, to offer Coala Heart Monitor Pro in Primary Care to insurance patients.
Coala named "Cool Vendor 2018" by Gartner, see press release here.
Coala is featured on TV4 Nyhetsmorgon (leading morning show on Swedish television), see more here.
Coala Life and Microsoft run joint seminars on AI and future of digital health at Almedalen week, Sweden
Coala Life is recognized by Red Herring as one of Europe's Top-100 start-ups.
Coala Life wins the People's Choice Award of the prestigious 2018 Grand Award of Design, see more here.
Publishing of clinical performance data at the 2018 Spring Cardiovascular Spring meeting in Stockholm, see results here.
Coala wins the EBAN (The European Trade Association for Business Angels, Seed Funds and Early Stage Market Players) eHealth Investment Seminar Pitch in Gothenburg, Sweden.
Results from joint-project with Praktikertjänst (the largest private healthcare provider in Sweden) is presented proving a reduction in specialist referrals with almost 40%, with reduced costs and satisfied users as results.
Coala strengthens the Board and organization with a fantastic quartet of industry leaders, see more here.
New apps released with trend monitoring, link to Apple Health and ability to link in external data such as blood pressure.
Coala wins the Makerstown 2018 Jury Award in Brusseles, among leading innovation and start-up companies from across Europe, see their press release here.
Coala celebrates 100,000 conducted ECG-measurements in Sweden using the Coala Heart Monitor.
Coala Life partners with Karolinska Institutet to run the RedHeart Study, read more here.
Coala Life finalist and part of the Serendipity Challenge 2018 event, among 50 of Swedens most innovative future leaders. Read more here.
Coala Life raises additional SEK 16 million (approx. USD 2 million) to accelerate growth, see press release here.
The University Hospital in Lund starts using the Coala Pro for smart and Digital cardiac assessments.
Coala Life wins the Startup World Cup finals in Sweden and heading for the global grand finale in Silicon Valley.
Coala Life is awarded the Digital Hospital Award 2018. Continued market roll-out in Sweden and first steps taken to go international.
Coala Life signs deal with global life science company Bayer, see press release here.
Coala Life raises additional growth capital and extends the Board, see pressrelease here.
Coala receives a major grant from the Swedish Governmental agency for Innovation Systems (Vinnova) to further develop Artificial Intelligence to enable early prediction of heart disease, see news release here.
Coala Life wins the Sweden Demo Day 2017 Pitch with over 100 finalists, read more here.
Coala Life launches Coala Labs in Sweden for smart, digital cardiac clinical investigations.
New set of algorithms are released for murmur detection by smart correlation of ECG and heart sounds, see release here.
Coala Life is awarded the prestigious Rising Star Award 2017 at the Swedish American Life Science Summit. Read press release here.
Coala is used in unique new clinical study on stroke patients, read more here.
Launch of the Coala Pro, a unique digital solution for caregivers and professional users to enable efficient, high performance yet simple arrhythmia assessments as well as diagnosing and managing patients with AFIB.
Coala Life wins the prestigious eHealthAward 2017, handed over by the Swedish Minister of Health.
Coala Life is honored as a finalist in the Swedish Mobile Awards 2017
Coala Life is a proud winner and part of "Sweden’s 33 hottest tech companies list 2017".
The Coala is launched in Sweden and sold online and in retail by LloydsPharmacy in Sweden. Consumers buy the Coala and subscribe for the service, and many Swedish health care providers access the data in the Coala Care Portal. Hjärtupplysningen (HeartCareLine) is established in Sweden as the first integrated care provider offering cardiac consultation based on the Coala for Premium subscribers.
Coala Life collaborates with industry leaders such as Microsoft, Ericsson, Sigma and Stockholm Heart Center in preparation for the upcoming market launch. Coala is CE-approved and Coala Life is ISO 13485 certified. LloydsPharmacy signs agreement to retail the Coala in Sweden.
The fourth generation technology platform and analysis algorithms are successfully verified. Coala is developed into a unique, medical technology system that allows users to monitor their heart any time, any place and very easily. An innovative and true e-health service in collaboration with caregivers. Coala Atlas is created. Coala Life is awarded additional patents.
Major Swedish studies confirm that preventative ECG screening leads to both earlier and more frequent detection of atrial fibrillation.
Coala Life AB is founded as a commercialization entity of the previous Cometech and R&D projects.
Coala research is initiated by Swedish entrepreneurs and physicians with the goal of developing wireless systems for digital monitoring and diagnosing of the heart. In 2007, the first generation Coala technology platform is developed and the first patent is approved. In 2013, Coala reaches a technological breakthrough. The fourth generation's new digital technology platform provides a completely new way of screening patients by digitizing heart sounds, simultaneously taking an ECG on the chest and analysing the data in the cloud.
The European Society for Cardiology (ESC) and the American Heart Association (AHA) publish the first, joint, international guidelines that recommend ECG monitoring to detect and diagnose atrial fibrillation.
A key publication included in the comprehensive Framingham study, confirms that atrial fibrillation increases the risk of stroke considerably.
The Dutch physiologist Willem Einthoven develops the first real equipment for recording ECG signals. A solution that weighed approximately 270 kg and required five people to conduct the examination.
1821 The analogue stethoscope is invented by the French physician Rene Laennec. Today, there are over 25 million units on the market.
A FEW OF OUR PARTNERS AND CREDITS
One of the greatest health problems of our time
Cardiovascular diseases are some of the most common causes of death in the world. More people die from cardiovascular diseases then from AIDS and all forms of cancer combined. In Sweden, four out of ten Swedes die of heart diseases. Many heart diseases can be detected and appropriately treated through preventive screening and diagnostics, including auscultation (listening to the heart) and ECG.
Atrial fibrillation, the silent killer
Atrial fibrillation (AFIB) is one of the most prevalent cardiovascular diseases. More than 30 million people are affected, which makes the disease one of the most common forms of heart disease in the world. In Sweden alone, more than 300,000 people are affected.
The problem is that many people do not know that they have a heart disease. If proper treatment is not provided, the risk of dying prematurely is twice as high. A person with AFIB runs five times the risk of suffering a stroke and three times the risk of heart failure. In addition, the risk increases with age. One of four people over the age of 40 are at risk of suffering from AFIB.
Among people over 75 years of age, AFIB can be considered a public health disease. Examining and detecting the symptoms early is key to avoiding more serious consequences. AFIB is detected using an ECG and typically treated with medication and cardioversion.
AFIB is detected most easily with an ECG, but since the fibrillation can occur irregularly, regular screening is often preferred. However this requires access to ECG equipment that can be carried or used regularly over a longer period of time. According to the recommendations from the Swedish Board of Health and Welfare (2015), caregivers should offer treatment by using blood thinning medications for all forms of atrial fibrillation. The estimate is that this will prevent 27,000 cases of stroke over the next 20 years. A further estimate is that 30,000 new individuals will be diagnosed with atrial fibrillation each year. In Sweden less than 50% of the patients with atrial fibrillation currently receive treatment using blood clot inhibitors. Lack of treatment is particularly common in terms of women and people over 80 years of age.
Cost simulations (Davidson et al) indicate that with the new blood-thinning medications, Swedish helathcare costs will increase (SEK 158 million over 20 years), while society saves large resources (SEK 3.352 billion), primarily through reduced costs of stroke care.
The assumption is that more widespread screening, and therefore more efficient diagnosis, can prevent approximately 27,000 cases of stroke, which will result in 57,000 additional years of life, with improved lifequality. The Swedish Dental and Pharmaceutical Benefits Agency (TLV) has completed an analysis of the costs of performing mobile screening from a lifespan perspective and the conclusion is that the cost is low.
In a study published in the European Journal of Health Economics 2011, the total costs for atrial fibrillation in Swedish society is estimated at SEK 6.6 billion in 2007. Of this total, SEK 5.8 billion is related to direct costs such as hospitalizations, transportation, doctors visits, pharmaceuticals and the treatment of complications. A large part of the cost comes from serious, subsequent diseases caused by atrial fibrillation.
National screening is expected to lead to both earlier and more detection of atrial fibrillation.
In June 2015 The Swedish National Board of Health and Welfare was commissioned by the government to investigate and implement a national screening program for atrial fibrillation. The study was conducted in collaboration with the Swedish Council on Medical and Social Assessment (SBU) and the Dental and Pharmaceutical Benefits Agency (TLV).The final report is to be be submitted to the Swedish government (Ministry of Health and Social Welfare) by 2017.
More efficient care processes are needed
A common problem for patients with atrial fibrillation is that they are at risk of facing long queues for care when they are looking for help at a hospital and may not always get the expert help they need. Many times, patients with atrial fibrillation are just treated for their temporary discomfort. An electrical conversion is performed, which briefly means that the patient receives an electric shock to restore balance to the heart rate, however there is a risk of delaying the decision of the actual problem and not creating a long-term treatment plan.
These poor treatment processes can affect both patients as well as society. The fact that many people are forced to drive to and from the hospital while fibrillation attacks are occurring, is cumbersome for the individual and results in large socio-economic expenses. Over the past 20 years, in-patient care as a result of atrial fibrillation has increased by 60%, and the cost for atrial fibrillation will likely increase, due to the increasing percentage of elderly persons in the population.
ECG does not detect all heart diseases
The stethoscope is used by more than 15 million physicians each day to listen to the heart. It is an easy and quick way to conduct an initial, subjective examination of the patient. The physician looks for murmurs, a medical term for the sounds that can be heard when swirls are formed in the blood that streams through the heart. Murmurs in the heart may be normal in healthy people (so-called physiological murmurs), but they can also be caused by problems and diseases with the heart valves, so-called valvular heart diseases. Murmurs are
normally not visible on an ECG. Valvular heart diseases can be congenital or acquired. In Sweden, age-related calcification of the heart valves is the most common cause for valve problems. Valvular diseases can consist of constrictions (stenosis) or leakage (insufficiency) which means that the valve does not close properly.
Aortic stenosis (constriction of the aortic valve) is the most common valvular disease in the industrialized world. Roughly two percent of those over 65 years of age, and five percent of everyone over 80 years of age are affected. The disease is often detected in connection with the physician listening to the heart using a stethoscope.
Valvular diseases can also lead to congestive heart failure. It is the most common cause of hospitalization in Sweden, resulting in major expenses. Roughly 200,000 Swedes suffer from heart failure, and among people over 80 years of age, up to ten percent have symptoms of congestive heart failure.
Many patients today have a poor understanding of their disease, which results in increased hospital readmissions.. Through screening and more efficient methods in terms of primary care, there is the potential to determine at an early stage which patients will need to be sent for further examination. This can lead to an increased quality of life for the patient as well as a reduction in the treatment period, which leads to efficiency gains.
The device is not yet available on the US market as it's not FDA cleared. FDA 510(k) is pending.